Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Shuqi, Wang, Mengchao, Zeng, Chuanxiu, Ou, Yan, Zhao, Lu, Wang, Dong, Chen, Liwei, Kong, Fanming, Yi, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248438/
https://www.ncbi.nlm.nih.gov/pubmed/37305582
http://dx.doi.org/10.3389/fonc.2023.1197698
_version_ 1785055374412349440
author Xie, Shuqi
Wang, Mengchao
Zeng, Chuanxiu
Ou, Yan
Zhao, Lu
Wang, Dong
Chen, Liwei
Kong, Fanming
Yi, Dan
author_facet Xie, Shuqi
Wang, Mengchao
Zeng, Chuanxiu
Ou, Yan
Zhao, Lu
Wang, Dong
Chen, Liwei
Kong, Fanming
Yi, Dan
author_sort Xie, Shuqi
collection PubMed
description Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice.
format Online
Article
Text
id pubmed-10248438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102484382023-06-09 Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma Xie, Shuqi Wang, Mengchao Zeng, Chuanxiu Ou, Yan Zhao, Lu Wang, Dong Chen, Liwei Kong, Fanming Yi, Dan Front Oncol Oncology Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice. Frontiers Media S.A. 2023-05-25 /pmc/articles/PMC10248438/ /pubmed/37305582 http://dx.doi.org/10.3389/fonc.2023.1197698 Text en Copyright © 2023 Xie, Wang, Zeng, Ou, Zhao, Wang, Chen, Kong and Yi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Shuqi
Wang, Mengchao
Zeng, Chuanxiu
Ou, Yan
Zhao, Lu
Wang, Dong
Chen, Liwei
Kong, Fanming
Yi, Dan
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title_full Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title_fullStr Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title_full_unstemmed Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title_short Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
title_sort research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248438/
https://www.ncbi.nlm.nih.gov/pubmed/37305582
http://dx.doi.org/10.3389/fonc.2023.1197698
work_keys_str_mv AT xieshuqi researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT wangmengchao researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT zengchuanxiu researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT ouyan researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT zhaolu researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT wangdong researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT chenliwei researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT kongfanming researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma
AT yidan researchprogressoftargetedtherapycombinedwithimmunotherapyforhepatocellularcarcinoma

Ejemplares similares